Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib resulted in longer progression-free survival and had somewhat less toxicity.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-01, Vol.378 (2), p.113-125
Hauptverfasser:	Soria, Jean-Charles, Ohe, Yuichiro, Vansteenkiste, Johan, Reungwetwattana, Thanyanan, Chewaskulyong, Busyamas, Lee, Ki Hyeong, Dechaphunkul, Arunee, Imamura, Fumio, Nogami, Naoyuki, Kurata, Takayasu, Okamoto, Isamu, Zhou, Caicun, Cho, Byoung Chul, Cheng, Ying, Cho, Eun Kyung, Voon, Pei Jye, Planchard, David, Su, Wu-Chou, Gray, Jhanelle E, Lee, Siow-Ming, Hodge, Rachel, Marotti, Marcelo, Rukazenkov, Yuri, Ramalingam, Suresh S
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Adult Aged Aged, 80 and over Aniline Compounds Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Chemotherapy Clinical outcomes Clinical trials Clonal deletion Disease-Free Survival Double-Blind Method Drug dosages Enzyme inhibitors Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - genetics Erlotinib Hydrochloride - therapeutic use Female Gefitinib Gene deletion Humans Inhibitor drugs Kaplan-Meier Estimate Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Male Medical research Metastasis Middle Aged Mutation Non-small cell lung carcinoma Oncology Patients Piperazines - adverse effects Piperazines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase receptors Protein-Tyrosine Kinases - antagonists & inhibitors Quinazolines - therapeutic use Survival Rate Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib resulted in longer progression-free survival and had somewhat less toxicity.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1713137